ArticleCHEST pulmonary2025
Mental Health Changes in Adolescents and Adults With Cystic Fibrosis After Initiation of Elexacaftor/Tezacaftor/Ivacaftor Therapy: Insights From the Longitudinal Resilience Impacted by Positive Stressful Events (RISE) Study.
Article in CHEST pulmonary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long-term effectiveness and safety of cystic fibrosis transmembrane conductance regulator modulators and their impact on the lives of people with cystic fibrosis.American journal of respiratory and critical care medicine · 2026Article
- Long-Term Adherence to Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis.Pulmonary therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Starting elexacaftor/tezacaftor/ivacaftor (ETI) is considered a positive life event for people with cystic fibrosis (pwCF). Nevertheless, some individuals report a decline in mental health after commencing ETI. Research Question: How do various mental health indicators of pwCF ≥ 12 years of age change after starting ETI, and can potentially more vulnerable subgroups, in terms of their mental health, be identified? Study Design and Methods: This was a prospective 60-week longitudinal cohort study with questionnaire-based measurements of mental health 12 weeks before (t0) and 12, 24, and 48 weeks after starting ETI (t1, t2, and t3, respectively). Subgroups were defined by age, sex, lung function at baseline, earlier use of any other modulator, and use of psychotropic medications. Data were analyzed using a covariance pattern model with a general variance covariance matrix. Results: In total, 174 (98.31%), 146 (82.49%), 141 (79.66%), and 142 (80.23%) participants completed or partially completed the questionnaires at t0, t1, t2, and t3, respectively. The data showed an overall statistically significant and clinically relevant improvement in psychosocial health ( Interpretation: In this study, pwCF experienced an improvement in all mental health indicators, except in anxiety symptoms. Clinical physicians should be aware that female patients, people with lower lung function, and those using psychotropic medications might be more prone to less favorable mental health improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.